Long-Acting Injectable Medications: What You Need to Know


This content is selected and managed by the Healthgrades editorial staff and is brought to you by an advertising sponsor.
x

This content is created or selected by the Healthgrades editorial team and is funded by an advertising sponsor. The content is subject to the Healthgrades medical review process for accuracy, balance and objectivity. The content is not edited or otherwise influenced by the advertisers appearing on this page except with the possible suggestion of the broad topic area. For more information, read the HealthGrades advertising policy.

ADVERTISEMENT
Needles One Milliliter

For people living with schizophrenia, taking maintenance medication to control symptoms and prevent relapse is vital. But what type of medication is best for you or your loved one? Long-acting injectable medications offer benefits that may be worth considering.

If you haven't heard of these medications, it's because they're largely underused in the United States. Doctors don't often prescribe them. Some reports estimate that as few as 5 to 19 percent of American schizophrenia patients are prescribed long-acting injectable antipsychotic medication, compared to rates of up to 50 percent in other countries. Why? Some doctors believe that their patients may not want to get injections. In addition, some offices aren't equipped to administer them.

How Injectable Medications Work

Long-acting medications, also called depot injections, are specially prepared antipsychotic drugs that are given by injection once or twice a month. They work by slowly releasing medication into the body over time. There are a handful of antipsychotic medications available in depot form. These include the older antipsychotics Haldol and Prolixin and newer generation antipsychotics Risperdal, Zyprexa, and Invega. These antipsychotics are also available in pill form. Oftentimes, people moving from an oral medication to a depot injectable continue taking the same antipsychotic drug in the injectable formulation. What changes is the form in which it's administered.

Help with Compliance

The greatest benefit of depot injections is that they help people comply with their maintenance medication plan. Forgetting to take your medication—even for a day or two—can greatly increase the risk for relapse and hospitalization. With depot-formulated antipsychotics, you only need to remember to get your injection once or twice a month.

In addition, injectable medications make it easier for doctors to tell if their patients are fully complying with their treatment plan. This helps doctors determine the effectiveness of the drug for their patients, helping them make sound treatment decisions. For example, if an antipsychotic doesn't work because it is taken inconsistently, it may be effective if given at a different dose or taken in a reliable way. In contrast, if symptoms are bothersome despite reliable medication intake at a sufficient dose and for a sufficient period of time, the medication might need to be changed.

Understanding Risks

The risks of depot injections are generally the same as the risks for antipsychotic drugs taken in pill form, although in general, side effects may be less frequent with depot injections. They may include weight gain, restlessness, stiffness, and dizziness. You should discuss these with your doctor. Although pain can occur at the injection site, it's usually mild and transient. People have commonly reported preferring depot injections over pills after trying both.

If you or your loved one has had a tough time sticking with a treatment plan, or if you prefer not to take a daily medication, talk with your doctor about depot injections. Using this long-acting medication may better fit your lifestyle and ensure that you don't miss the medication you need to help you achieve your life goals. 

Medical Reviewers: L Marcellin, MD, MPH; Last Review Date: Nov 11, 2012

© 2015 Healthgrades Operating Company, Inc. All rights reserved. May not be reproduced or reprinted without permission from Healthgrades Operating Company, Inc. Use of this information is governed by the Healthgrades User Agreement.

View Sources

Medical References

  1. “Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making.” G Foussias and G Remington. Canadian Journal of Psychiatry. March 2010, vol. 55, no. 3, pp. 117-22.;
  2. “Challenges in Preventing Schizophrenia.” Harvard Mental Health Letter. December 1, 2009.;
  3. “Encouraging Patients to Take Medications as Prescribed.” Harvard Mental Health Letter. January 2010.;
  4. “Partial Compliance With Antipsychotic Medication is Common in Patients with Schizophrenia.” C. Rummel-Kluge et al. The Australian and New Zealand Journal of Psychiatry. May 2008. Vol. 42, no. 5, pp. 382-8.;
  5. “The Use of Depot Medications in the Treatment of Schizophrenia.” J. Davis. American Journal of Psychiatry. February 2010, vol. 167, no. 2, pp. 125-6.;
  6. “Use of Depot Antipsychotic Medications for Medication Nonadherence in Schizophrenia.” J West et al. Sept. 2008, vol. 34, no. 5, pp. 995-1001.;
  7. “List Results: Schizophrenia.” U.S. National Institutes of Health. Accessed May 25, 2010 (http://clinicaltrials.gov/search/open/condition=%22Schizophrenia%22);
  8. “Columbia’s Dr. Jeffrey Lieberman Leads Nationwide Effort to Develop Early Intervention for First Signs of Schizophrenia.” Columbia University Medical School. July 21, 2009 (http://cumc.columbia.edu/news/press_releases/Early_Intervention_Schizophrenia.html);
  9. North American Prodrome Longitudinal Study (http://napls.psych.ucla.edu/);
  10. “Research.” Johns Hopkins Medicine. Accessed May 25, 2010 (http://www.hopkinsmedicine.org/psychiatry/specialty_areas/schizophrenia/research.html);
  11. “Understanding Schizophrenia and Recovery.” National Alliance on Mental Illness. August 2008 (http://www.nami.org/Content/Microsites316/NAMI_PA,_Cumberland_and_Perry_Cos_/Discussion_Groups559/No...;
  12. “Schizophrenia.” National Alliance on Mental Illness. February 2007 (http://www.nami.org/Template.cfm?Section=By_Illness&Template=/TaggedPage/TaggedPageDisplay.cfm&TPLID...;
  13. “Impaired Brain Connections Traced to Schizophrenia Mutation.” National Institute of Mental Health. March 31, 2010 (http://www.nih.gov/news/health/mar2010/nimh-31.htm);
  14. “Schizophrenia.” National Institute of Mental Health. 2009 (http://www.nimh.nih.gov/health/publications/schizophrenia/complete-index.shtml#pub7);
  15. “Depot Medication.” The Royal College of Psychiatrists. January 2010 (http://www.rcpsych.ac.uk/mentalhealthinfo/problems/schizophrenia/depotmedication.aspx);
  16. “Benefits of Dept Antipsychotics.” Schizophrenia Daily News Blog. Sept. 5, 2005 (http://www.schizophrenia.com/sznews/archives/002371.html);

E-mail this page to your friends.